Skip to main content
S&P 5007,688.62+1.58%DOW53,356.12+3.03%NASDAQ25,736.51+1.44%BTC$80,787.00+5.07%ETH$2,431.65+7.47%GOLD$4,134.30+1.51%OIL$87.17-1.08%
Smart Investors Daily
SID Premium
MN

NASDAQ · MNOV

MediciNova, Inc.

Healthcare · Biotechnology

$1.45

Up+$0.03 (+2.11%)

Updated Nov 5, 2026, 3:27 AM

SID Score

4.3/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
74.55M
P/E ratio
-6.31
Dividend yield
0.00%
52-week range
$1.22 – $3.90
Volume
50.04K
Avg. volume
972.45K

Price performance · MNOV

MNOV price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 4, 2026

MNOV closed at $1.45 after 21 trading sessions, down 9.94% for the selected period.

Last close
$1.45
Period change
-9.94%
Period low
$1.36
Period high
$1.61
Daily close
View OHLC price history
MNOV OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 4, 2026$1.44$1.5375$1.42$1.4550.04K
Nov 3, 2026$1.43$1.49$1.41$1.4257.07K
Nov 2, 2026$1.40$1.53$1.40$1.4447.87K
Oct 30, 2026$1.42$1.42$1.38$1.4029.68K
Oct 29, 2026$1.46$1.50$1.39$1.4053.2K
Oct 28, 2026$1.42$1.4899$1.401$1.4725.01K
Oct 27, 2026$1.42$1.42$1.39$1.4137.75K
Oct 26, 2026$1.42$1.47$1.40$1.4089.91K
Oct 23, 2026$1.40$1.42$1.39$1.3925.51K
Oct 22, 2026$1.41$1.42$1.38$1.4130.49K
Oct 21, 2026$1.37$1.41$1.37$1.4132.6K
Oct 20, 2026$1.40$1.44$1.358$1.3637.12K
Oct 19, 2026$1.40$1.45$1.37$1.40144.24K
Oct 16, 2026$1.47$1.4988$1.42$1.4280.28K
Oct 15, 2026$1.47$1.53$1.45$1.4558.76K
Oct 14, 2026$1.51$1.55$1.46$1.4796.19K
Oct 13, 2026$1.56$1.56$1.50$1.5034.8K
Oct 12, 2026$1.49$1.575$1.4799$1.54127.79K
Oct 9, 2026$1.54$1.565$1.52$1.5269.9K
Oct 8, 2026$1.60$1.61$1.53$1.54109.38K
Oct 7, 2026$1.65$1.68$1.60$1.6178.11K

Latest MNOV news

The latest Smart Investors Daily articles mentioning MNOV.

Stock researchCompany · Overview

MNOV research

Overview

Company profile and research snapshot.

Company profile

MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's strategies are to focus its developing activities on therapeutics for neurological disorders and fibrotic diseases.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
MNOV recent ratings
DateFirmRatingTarget
Sep 17, 2026Roth CapitalBuy—
May 4, 2026D. Boral CapitalBuy—
Mar 23, 2026Maxim GroupBuy—
Mar 16, 2026HC Wainwright & Co.Buy—
Jan 30, 2026D. Boral CapitalBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 12, 2026

MediciNova CEO Provides Shareholder Update

LA JOLLA, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) (the “Company”), today provides shareholders an update on key findings from the recent topline results of its Phase 2 clinical trial evaluating MN-001 for the treatment of nonalcoholic fatty liver disease and hypertriglyceridemia associated with type 2 diabetes mellitus in the fo

Benzinga · Oct 12, 2026

MediciNova Provides Update On Recent Topline Results Of Its Phase 2 Clinical Trial Evaluating MN-001 For Treatment Of Nonalcoholic Fatty Liver Disease And Hypertriglyceridemia Associated With Type 2 Diabetes Mellitus; At End Of The 24-Week Period, Serum Triglycerides, Liver Fat, And Body Weight Were Also Reduced In The MN-001 Group Compared With Placebo, Although These Differences Did Not Reach Statistical Significance

To Fellow Shareholders,We continue to advance our key programs to create viable treatments for both metabolic disease and amyotrophic lateral sclerosis (ALS). Recently, we announced topline results of our Phase 2

Yahoo · Oct 6, 2026

MediciNova to Participate in the Maxim Growth Summit

LA JOLLA, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) (the “Company”), announces that management will participate in the Maxim Growth Summit taking place October 12-14, 2026, at the Hard Rock Hotel New York. Management will be available for one-on-one meetings with investors registered for the event. Investors interested in scheduli

Yahoo · Sep 28, 2026

MediciNova Drug Falls Short on Liver Fat Parameter, Stock Tumbles

MediciNova Inc. (NASDAQ:MNOV) stock is trading lower on Monday after the company reported mixed topline results from its Phase 2 clinical trial evaluating MN-001 (tipelukast) for hypertriglyceridemia and nonalcoholic fatty liver disease (NAFLD) associated with type 2 diabetes mellitus. The exploratory study highlighted improvements in cardiovascular lipid markers, alongside positive trends in liver fat reduction and body weight loss. Phase 2 Trial Design And Efficacy Findings The MN-001-NATG-202

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By